Clinical Trial

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-03-02; most recent amendment 2025-02-23.
Status change: Active, Not Recruiting → Recruiting 2021-07-30
Trial Details
NCT Number NCT04781634
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions B-ALL
Enrollment 40 participants
Start Date 2021-03-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-25